Perspective Therapeutics(CATX) - 2025 Q1 - Quarterly Results

Exhibit 99.1 Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal 3Q 2024 Results • Advancing investigation of [ 212Pb]VMT01 as a monotherapy and in combination with the anti-PD-1 antibody, nivolumab, in patients with previously treated metastatic melanoma, based on preliminary results presented at the 21 stInternational Congress of the Society of Melanoma Research in October • Presenting initial results from the company-sponsored Phase 1/2a study of [ 212Pb]VMT-α-NET in patients ...